Two medicines, side by side
Aclidinium vs aspirin
Aclidinium is labeled for copd; aspirin for pain, cough and cold and fever. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of aclidinium since 2012 and of aspirin since 1965. Pharmacies paid $344.55 per unit (Tudorza pressair 400 mcg inhal) and $0.0142 per aspirin ec 81 mg tablet (NADAC, October 7, 2026); the strengths differ and one is a brand and one a generic, so the two prices are not like for like.
Check it at the source: the aclidinium FDA label on DailyMed (effective August 1, 2022); the aspirin FDA label on DailyMed (effective September 9, 2025).
Highlights of the aclidinium record
Aclidinium (Tudorza Pressair) · label of August 1, 2022
Used for
From the label: indicationsTUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). TUDORZA PRESSAIR is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
On the market
- Earliest approval on file
- July 23, 2012
- Generic labelers
- none listed
- Pharmacy cost
- $344.55 per unit
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the aspirin record
Aspirin (Measurin) · label of September 9, 2025
Used for
From the label: indicationsTemporarily relieves headache toothache pain and fever of colds muscle pain menstrual pain minor pain of arthritis
On the market
- Earliest approval on file
- June 25, 1965
- Generic labelers
- none listed
- Pharmacy cost
- $0.0142 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 1
Source: FDA drug labels via openFDA (Aclidinium label of August 1, 2022, Aspirin label of September 9, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do aclidinium and aspirin differ on the record?
| Aclidinium | Aspirin | |
|---|---|---|
| Labeled for | COPD | Pain, Cough and cold, Fever |
| Pharmacologic class | Anticholinergic | n/a |
| How it works (label) | Aclidinium bromide is a long-acting antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M 1 to M 5 . | n/a |
| Half-life (label) | After dry powder inhalation, urinary excretion of aclidinium is about 0.09% of the dose and the estimated effective half-life is 5 to 8 hours. | n/a |
| Earliest approval on file (Drugs@FDA) | July 23, 2012 | June 25, 1965 |
| First generic approved | none | none |
| Generic labelers (NDC) | none listed | none listed |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $344.55 per unit (Tudorza pressair 400 mcg inhal) | $0.0142 per tablet (Aspirin ec 81 mg tablet) |
| 12-month price change | n/a | -2% |
| Boxed warning | No | No |
| Shortage now | No current entry | A presentation being discontinued |
| Recalls recorded | 0 | 1 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 6,373 | 534,208 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What do the labels say about using others of their kind?
Aclidinium label, drug interactionsAvoid administrations of TUDORZA PRESSAIR with other anticholinergic-containing drugs.
Source: FDA drug labels via openFDA
What next?
- Alternatives to aclidinium
- every medicine labeled for the same conditions